

Supplementary Material to “Real-world setting cost-effectiveness analysis of thymoglobulin versus no induction therapy in kidney transplant recipients with low risk for graft loss”

TABLE S2 INCIDENCE OF CLINICAL EVENTS INCLUDED IN THE MARKOV MODEL AFTER 4 YEARS.

Outcome	No induction/ r-ATG	References
Graft loss (without previous AR)	$1-(1-5.5\%)^{(1/5)} = 1.1\%$	Jalalzadeh, 2015 ¹³
Graft loss (with previous AR)	$1-(1-63.2\%)^{(1/5)} = 18.1\%$	Jalalzadeh, 2015 ¹³
Death with a functioning graft	$1-(1-10.1\%)^{(1/5)} = 2.1\%$	Cristelli, 2013 ¹⁴
Death after graft loss	$1-(1-33\%)^{(1/3)} = 12.5\%$	Gill, 2002 ¹⁵

r-ATG: rabbit antithymocyte globulin; AR: acute rejection.